FIGURE: 1 / 6
Keep as concentrated solution.
Predicted reactivity: Mouse (100%), Rat (100%), Sheep (100%).
Positive Control: NIH-3T3 (starvation for 16 hr), NIH-3T3 (starvation for 16 hr and 200 ng/mL EGF treatment for 0.5 hr), 293T, 293T (200 ng/mL EGF treatment for 0.5 hr).
Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
FRAP1 (mTOR) is a serine/threonine kinase that plays a critical role in cellular growth and proliferation. Perturbations in the mTOR/PI3-kinase/AKT pathway are associated with numerous forms of cancer. FRAP1 is also the target of rapamycin and its analogues, which are currently used as immunosuppressants and cancer therapeutics. Mutations affecting the gene results in Smith-Kingsmore syndrome.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: angiopoietin-like factor CDT6; FK506 binding protein 12-rapamycin associated protein 1; FK506 binding protein 12-rapamycin associated protein 2; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP-rapamycin associated protein; FKBP-rapamycin associated protein (FRAP); FKBP-rapamycin-associated protein FRAP; FKBP12-rapamycin complex-associated protein; FKBP12-rapamycin complex-associated protein 1; m-TOR; Mammalian target of rapamycin; Mechanistic target of rapamycin; mechanistic target of rapamycin (serine/threonine kinase); mTOR; mTORC1; Rapamycin and FKBP12 target 1; rapamycin associated protein FRAP2; Rapamycin target protein 1; RAPT1; Serine/threonine-protein kinase mTOR
Gene Aliases: 2610315D21Rik; AI327068; flat; FRAP; FRAP1; FRAP2; MTOR; RAFT1; RAPT1; SKS